Plain-English translation of NCT06488482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with advanced melanoma need a full 12 months of a PD-1 inhibitor medication after surgery, or if 6 months would work just as well. Researchers want to find out if shorter treatment can prevent melanoma from returning while reducing side effects and costs. You would be randomly assigned to receive either 6 months or 12 months of this medication.
Currently, doctors routinely give 12 months of this medication after melanoma surgery, but no one has actually proven that a full year is necessary. This medication can cause serious side effects and is very expensive; shorter treatment could help patients avoid unnecessary harm and reduce healthcare costs without sacrificing effectiveness.
You likely qualify if…
You likely don't qualify if…
You would visit a cancer clinic regularly to receive intravenous infusions of the medication—either every 3 weeks (if receiving pembrolizumab) or every 4 weeks (if receiving nivolumab). Your participation would last either 6 or 12 months depending on which group you're randomly assigned to. During treatment, you'll have regular check-ups, blood tests, and imaging scans to monitor for side effects and watch for any signs that melanoma is returning.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Finland
Norway
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gustav J Ullenhag, professor
Uppsala University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.